Allergic reactions might be expected, including rash, nasal congestion, cough, dry throat, eye irritation, or anaphylactic shock. Overdosage of cephalosporins can cause cerebral irritation leading to convulsions.
Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Probenecid | The serum concentration of Cefuroxime can be increased when it is combined with Probenecid. |
| Foscarnet | The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Foscarnet. |
| Mannitol | The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefuroxime. |
| Tenofovir disoproxil | Cefuroxime may increase the nephrotoxic activities of Tenofovir disoproxil. |
| Tenofovir alafenamide | Cefuroxime may increase the nephrotoxic activities of Tenofovir alafenamide. |
| Tenofovir | Cefuroxime may increase the nephrotoxic activities of Tenofovir. |
| Olanzapine | Olanzapine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cimetidine | Cimetidine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nizatidine | Nizatidine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ranitidine | Ranitidine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Famotidine | Famotidine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methantheline | Methantheline can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Promethazine | Promethazine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Doxepin | Doxepin can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Asenapine | Asenapine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Metiamide | Metiamide can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Roxatidine acetate | Roxatidine acetate can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lafutidine | Lafutidine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lavoltidine | Lavoltidine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Niperotidine | Niperotidine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Epinastine | Epinastine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminium | The serum concentration of Cefuroxime can be decreased when it is combined with Aluminium. |
| Magnesium oxide | The serum concentration of Cefuroxime can be decreased when it is combined with Magnesium oxide. |
| Sodium bicarbonate | The serum concentration of Cefuroxime can be decreased when it is combined with Sodium bicarbonate. |
| Aluminum hydroxide | The serum concentration of Cefuroxime can be decreased when it is combined with Aluminum hydroxide. |
| Calcium carbonate | The serum concentration of Cefuroxime can be decreased when it is combined with Calcium carbonate. |
| Magaldrate | The serum concentration of Cefuroxime can be decreased when it is combined with Magaldrate. |
| Magnesium hydroxide | The serum concentration of Cefuroxime can be decreased when it is combined with Magnesium hydroxide. |
| Magnesium trisilicate | The serum concentration of Cefuroxime can be decreased when it is combined with Magnesium trisilicate. |
| Magnesium carbonate | The serum concentration of Cefuroxime can be decreased when it is combined with Magnesium carbonate. |
| Bismuth subnitrate | The serum concentration of Cefuroxime can be decreased when it is combined with Bismuth subnitrate. |
| Magnesium silicate | The serum concentration of Cefuroxime can be decreased when it is combined with Magnesium silicate. |
| Aluminium acetoacetate | The serum concentration of Cefuroxime can be decreased when it is combined with Aluminium acetoacetate. |
| Hydrotalcite | The serum concentration of Cefuroxime can be decreased when it is combined with Hydrotalcite. |
| Magnesium peroxide | The serum concentration of Cefuroxime can be decreased when it is combined with Magnesium peroxide. |
| Almasilate | The serum concentration of Cefuroxime can be decreased when it is combined with Almasilate. |
| Aluminium glycinate | The serum concentration of Cefuroxime can be decreased when it is combined with Aluminium glycinate. |
| Aloglutamol | The serum concentration of Cefuroxime can be decreased when it is combined with Aloglutamol. |
| Calcium silicate | The serum concentration of Cefuroxime can be decreased when it is combined with Calcium silicate. |
| Aluminium phosphate | The serum concentration of Cefuroxime can be decreased when it is combined with Aluminium phosphate. |
| Pantoprazole | The serum concentration of Cefuroxime can be decreased when it is combined with Pantoprazole. |
| Rabeprazole | The serum concentration of Cefuroxime can be decreased when it is combined with Rabeprazole. |
| Omeprazole | The serum concentration of Cefuroxime can be decreased when it is combined with Omeprazole. |
| Lansoprazole | The serum concentration of Cefuroxime can be decreased when it is combined with Lansoprazole. |
| Esomeprazole | The serum concentration of Cefuroxime can be decreased when it is combined with Esomeprazole. |
| Dexlansoprazole | The serum concentration of Cefuroxime can be decreased when it is combined with Dexlansoprazole. |
| Dexrabeprazole | The serum concentration of Cefuroxime can be decreased when it is combined with Dexrabeprazole. |
| Sodium zirconium cyclosilicate | The serum concentration of Cefuroxime can be decreased when it is combined with Sodium zirconium cyclosilicate. |
| Vonoprazan | The serum concentration of Cefuroxime can be decreased when it is combined with Vonoprazan. |
| Picosulfuric acid | The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefuroxime. |
| Cyclosporine | The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefuroxime. |
| Icosapent | The risk or severity of nephrotoxicity can be increased when Icosapent is combined with Cefuroxime. |
| Cefotiam | The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Cefuroxime. |
| Mesalazine | The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefuroxime. |
| Cefmenoxime | The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Cefuroxime. |
| Cefmetazole | The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Cefuroxime. |
| Indomethacin | The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Cefuroxime. |
| Triamterene | The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Cefuroxime. |
| Cefpiramide | The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Cefuroxime. |
| Loracarbef | The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cefuroxime. |
| Cefalotin | The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Cefuroxime. |
| Nabumetone | The risk or severity of nephrotoxicity can be increased when Nabumetone is combined with Cefuroxime. |
| Ketorolac | The risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Cefuroxime. |
| Tenoxicam | The risk or severity of nephrotoxicity can be increased when Tenoxicam is combined with Cefuroxime. |
| Celecoxib | The risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Cefuroxime. |
| Cefotaxime | The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cefuroxime. |
| Tolmetin | The risk or severity of nephrotoxicity can be increased when Tolmetin is combined with Cefuroxime. |
| Rofecoxib | The risk or severity of nephrotoxicity can be increased when Rofecoxib is combined with Cefuroxime. |
| Fenoprofen | The risk or severity of nephrotoxicity can be increased when Fenoprofen is combined with Cefuroxime. |
| Valdecoxib | The risk or severity of nephrotoxicity can be increased when Valdecoxib is combined with Cefuroxime. |
| Diclofenac | The risk or severity of nephrotoxicity can be increased when Diclofenac is combined with Cefuroxime. |
| Sulindac | The risk or severity of nephrotoxicity can be increased when Sulindac is combined with Cefuroxime. |
| Bacitracin | The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Cefuroxime. |
| Amphotericin B | The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefuroxime. |
| Cephaloglycin | The risk or severity of nephrotoxicity can be increased when Cephaloglycin is combined with Cefuroxime. |
| Adefovir dipivoxil | The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Cefuroxime. |
| Pentamidine | The risk or severity of nephrotoxicity can be increased when Pentamidine is combined with Cefuroxime. |
| Mefenamic acid | The risk or severity of nephrotoxicity can be increased when Mefenamic acid is combined with Cefuroxime. |
| Naproxen | The risk or severity of nephrotoxicity can be increased when Naproxen is combined with Cefuroxime. |
| Sulfasalazine | The risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Cefuroxime. |
| Phenylbutazone | The risk or severity of nephrotoxicity can be increased when Phenylbutazone is combined with Cefuroxime. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Cefuroxime is combined with Meloxicam. |
| Carprofen | The risk or severity of nephrotoxicity can be increased when Carprofen is combined with Cefuroxime. |
| Tacrolimus | The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefuroxime. |
| Etacrynic acid | The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefuroxime. |
| Ceforanide | The risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Cefuroxime. |
| Salicylic acid | The risk or severity of nephrotoxicity can be increased when Salicylic acid is combined with Cefuroxime. |
| Acetylsalicylic acid | The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefuroxime. |
| Hydrochlorothiazide | The risk or severity of nephrotoxicity can be increased when Hydrochlorothiazide is combined with Cefuroxime. |
| Balsalazide | The risk or severity of nephrotoxicity can be increased when Balsalazide is combined with Cefuroxime. |
| Cefditoren | The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Cefuroxime. |
| Atazanavir | The risk or severity of nephrotoxicity can be increased when Atazanavir is combined with Cefuroxime. |
| Colistimethate | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Cefuroxime. |
| Cefapirin | The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Cefapirin. |
| Cefprozil | The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Cefprozil. |
| Olsalazine | The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Olsalazine. |
| Lumiracoxib | The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Lumiracoxib. |
| Cefamandole | The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Cefamandole. |
| Cefazolin | The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Cefazolin. |
| Cefonicid | The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Cefonicid. |